Roche ends KRAS deal with Hookipa Pharma, as biotech lays off 30% of staff

Roche is waving goodbye to a KRAS program it partnered on less than a year and a half ago.

The Swiss conglomerate ended its collaboration agreement with Hookipa Pharma that aimed to co-develop a compound called HB-700, Hookipa announced Monday. The deal, signed in October 2022,…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks